September's semaglutide news brings new research in younger children, clearer heart-care guidance, and changes to access and prescribing instructions. These developments affect different products and different people. They don't automatically change an existing prescription or establish benefits for a compounded preparation, a medicine made by a pharmacy for an individual prescription.
As of September 10, 2026, the day this article was written, Novo Nordisk had reported STEP Young results on September 7. The quarter's other changes are below, newest first.
Changelog
September 7, 2026 — first STEP Young results. Novo's announcement described a trial of 165 children ages 6 to under 12. About 2 in 5 receiving semaglutide fell below the obesity threshold at 68 weeks: 40.4%, versus 0% with placebo, an inactive comparison treatment. That estimate assumes all children stayed on treatment. Both groups received food and activity support. These are company-reported first results; semaglutide for children explains the age-label distinction.
September 1, 2026 — online-seller letters posted. FDA's index records five letters dated August 24; one names semaglutide and says the seller's products were marketed as unapproved drugs. The warning-letter explainer covers their scope; they concern particular sellers, not every prescribed formulation.
August 28, 2026 — heart-failure guidance changed. The European Society of Cardiology announced new guidance that includes semaglutide or tirzepatide for selected people with obesity and symptomatic heart failure, when the heart struggles to meet the body's needs. Its recommendation table says treatment should be considered, rather than prescribed automatically. The heart-failure guideline guide explains who fits.
July 29, 2026 — oral alcohol-use trial published. In Schacht and colleagues' trial, published online in the American Journal of Psychiatry, 50 adults received semaglutide tablets or placebo for eight weeks. Heavy-drinking days were lower with semaglutide, but the main measure—craving during a laboratory task—did not clearly improve. That mixed result supports further study, not a new treatment claim.
July 1, 2026 — Medicare Bridge began. CMS's product list, last modified August 6, includes Wegovy injections and tablets for eligible beneficiaries seeking weight management. Compounded semaglutide is not included. The separate Medicare coverage guide explains eligibility; having Medicare alone doesn't settle access.
June 29, 2026 — Canadian authorization for Sevmia. Health Canada authorized Apotex's version of Wegovy for weight management. Authorization is not a launch announcement or a U.S. decision. Compounding is not the same route; the generic semaglutide guide explains that distinction.
June 26, 2026 — compounding comment deadline extended. FDA's Federal Register notice extended comments through July 30 on its proposal to exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list. That list concerns ingredients used by outsourcing facilities, compounding operations that can prepare medicine for clinic stock. Closing comments is not itself a final decision.
June 18, 2026 — Wegovy label updated. DailyMed's prescribing information carries “Revised: 6/2026.” The June addition concerns FlexTouch, a pen containing four doses for one person: sharing it can transmit infections even when the needle changes. The label update does not establish interchangeability with a compounded vial.
What the semaglutide news means for an adult
Semaglutide copies GLP-1, a gut hormone involved in fullness and blood sugar. Its established branded uses depend on the finished product: Ozempic injection covers type 2 diabetes and certain heart and kidney risks in specified diabetes populations. Rybelsus and Ozempic tablets cover blood sugar and certain heart risks. Wegovy covers weight management and certain heart risks; its injection also has a specific liver-disease use.
The new heart guidance builds on trials such as STEP-HFpEF, a 2023 study of 529 adults with obesity and heart failure whose pumping squeeze was relatively preserved. After 52 weeks, scores on a questionnaire about symptoms and limits on daily activities improved by 16.6 points with semaglutide and 8.7 with placebo, on a 100-point scale where higher means better (Kosiborod and colleagues, New England Journal of Medicine). It was evidence about that patient group, not every kind of heart failure.
Tirzepatide also appears in the new guidance, but it acts on an additional gut-hormone pathway. Choosing between the two remains a separate clinical decision. The guideline doesn't suggest taking them together, and one medicine's trial numbers don't transfer to the other.
What remains separate for compounded semaglutide
Through Promise, semaglutide is dispensed as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved. The same distinction applies to Promise's compounded tirzepatide. FDA explains that compounded preparations do not receive its review for safety, effectiveness or quality before marketing.
A brand's label, Canadian authorization, or research announcement doesn't establish that a compounded preparation was studied.
As of September 10, 2026, the day this article was written, FDA's published policy still described a separate route under section 503A, the rules for individual prescriptions. Those rules generally restrict repeated copies of commercially available medicines; a prescriber's documented finding that a change makes a significant difference for one patient matters.
A licensed provider may still prescribe a compounded formulation when the clinical and legal conditions are met; that decision is between the patient and the doctor.
The seller letters make accountability especially relevant. A prescribed route connects an identified clinician, a licensed U.S. pharmacy, the dispensing label and a traceable batch. It also gives a patient somewhere to report a reaction and lets the pharmacy contact affected patients if a batch has a problem. Those are concrete questions a seller's laboratory wording cannot answer.
What a provider considers now
The news comes after the medical history. The review includes a personal or family history of medullary thyroid carcinoma, a particular thyroid cancer, or MEN 2, an inherited tumor condition. The Wegovy label rules out use in those circumstances.
Pancreas or gallbladder problems, severe slow stomach emptying, pregnancy plans, diabetes-related eye disease, and other medicines also matter. Vomiting or diarrhea can cause dehydration and strain the kidneys. The prescriber sets the dose and follow-up plan around the person's history and response.
At Promise, a licensed provider reviews every request and not everyone qualifies. A specialist's input can be part of that review when heart failure or another complex condition is involved.
What to watch next
The next useful pediatric evidence is the full STEP Young report, including side-effect tables and longer follow-up; Novo's September announcement says detailed results are planned for November. For compounding, the important document would be FDA's final decision on the 503B proposal, separate from the comment deadline. For access, CMS can revise its covered-product list.
Each update needs the same plain question: which product, which people, and what actually changed? Those details make the news useful at a medical visit.